Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)

被引：0

作者：

Popat, Rakesh ^{[1
]}

Richardson, Paul G. ^{[2
]}

Trudel, Suzanne ^{[3
]}

Quach, Hang ^{[4
]}

Lonial, Sagar ^{[5
]}

Orlowski, Robert Z. ^{[6
]}

Kim, Kihyun ^{[7
]}

Mateos, Maria-Victoria ^{[8
]}

Pawlyn, Charlotte ^{[9
,10
]}

Ramasamy, Karthik ^{[11
]}

Martinez-Lopez, Joaquin ^{[12
]}

Casas-Aviles, Ignacio ^{[13
]}

Spirli, Alessia ^{[14
]}

Gong, Jing ^{[15
]}

Amatangelo, Michael ^{[15
]}

Katz, Jessica ^{[15
]}

Maciag, Paulo ^{[15
]}

Peluso, Teresa ^{[14
]}

Bahlis, Nizar J. ^{[16
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia

[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[7] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[8] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[9] Royal Marsden NHS Fdn, London, England

[10] Inst Canc Res, London, England

[11] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England

[12] Univ Complutense Madrid, Hosp Octubre, Hosp 12 Octubre, Dept Hematol,CIBERONC, Madrid, Spain

[13] Hosp San Pedro Alcantara, Caceres, Spain

[14] Celgene Int Sarl Bristol Myers Squibb Co, Boudry, Switzerland

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO15

引用

页码：66 / 67

页数：2

共 50 条

[31] Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Richardson, Paul G.
Bensinger, William I.
Huff, Carol Ann
Costello, Caitlin L.
Lendvai, Nikoletta
Berdeja, Jesus G.
Anderson, Larry D., Jr.
Siegel, David S.
Lebovic, Daniel
Jagannath, Sundar
Laubach, Jacob P.
Stockerl-Goldstein, Keith E.
Kwei, Long
Clow, Fong
Elias, Laurence
Salman, Zeena
Graef, Thorsten
Bilotti, Elizabeth
Vij, Ravi
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 821 - 830
[32] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
Richardson, Paul
Jagannath, Sundaf
Raje, Noopur
Jakubowiak, Andrzej
Lonial, Sagar
Ghobrial, Irene
Schlossman, Robert
Mazumder, Amitabha
Munshi, Nikhil
Colson, Kathleen
McKenney, Mary
Farrell, Melissa
Lunde, Laura
Giove, Lawrence
Kaster, Sarah
Mitsiades, Constantine
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth
BLOOD, 2007, 110 (11) : 797A - 797A
[33] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
Bilotti, El
Vesole, D.
Richter, J.
McNeill, A.
Anand, P.
Bednarz, U.
Ivanovski, K.
McBride, L.
Raucci, L.
Batra, V.
Siegel, D.
HAEMATOLOGICA, 2013, 98 : 323 - 324
[34] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Paulus, Aneel
Alegria, Victoria R.
Laplant, Betsy
Moustafa, Muhamad Alhaj
Chapin, Dustin
Jackson, Keisha
Jani, Prachi
Ahmed, Salman
Edwards, Brett
Manna, Alak
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
BLOOD, 2019, 134
[35] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
Lonial, Sagar
Abdallah, Al-Ola
Anwer, Faiz
Badros, Ashraf Z.
Bhutani, Manisha
Khan, Abdullah
Lipe, Brea
Oriol, Albert
White, Darrell
Amatangelo, Michael
Jin, Kexin
Masin, Mark
Nguyen, Vi
Amin, Alpesh
Maciag, Paulo
van de Donk, Niels W. C. J.
BLOOD, 2022, 140 : 4398 - 4400
[36] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Duran, M.
Tombuloglu, M.
Tobu, M.
Vural, F.
Sahin, F.
Patir, P.
Uysal, A.
Saydam, G.
LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
[37] FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
Palumbo, A.
Magarotto, V.
Sonneveld, P.
Plesner, T.
Paba-Prada, C.
Voorhees, P.
Mellqvist, U. H.
Byrne, C.
Harmenberg, J.
Nordstrom, E.
Zubair, H.
Richardson, P. G.
HAEMATOLOGICA, 2016, 101 : 85 - 85
[38] Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Richardson, Paul G.
Mikhael, Joseph
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Campana, Frank
Gao, Lei
Dubin, Franck
Wack, Claudine
Anderson, Kenneth C.
BLOOD, 2016, 128 (22)
[39] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Ray
Wang, Jim
Masterson, Tara
Nottage, Kerri
Schecter, Jordan
Chiu, Christopher
Khokhar, Nushmia
Ahmadi, Tahamtan
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
[40] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
Dholaria, Bhagirathbhai
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Harmut
Martin, Thomas
Morillo, Daniel
Reece, Donna
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, M. Damiette
Wasch, Ralph
van de Donk, Niels
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477

← 1 2 3 4 5 →